

# Irene Gutiérrez-Cañas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7505609/publications.pdf>

Version: 2024-02-01

41  
papers

1,435  
citations

236612

25  
h-index

315357

38  
g-index

41  
all docs

41  
docs citations

41  
times ranked

1743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Human CD4+CD45RA+ T Cells Behavior after In Vitro Activation: Modulatory Role of Vasoactive Intestinal Peptide. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2346.	1.8	0
2	Enhanced Susceptibility of Galectin-1 Deficient Mice to Experimental Colitis. <i>Frontiers in Immunology</i> , 2021, 12, 687443.	2.2	4
3	Proteomic Analysis of Synovial Fibroblasts and Articular Chondrocytes Co-Cultures Reveals Valuable VIP-Modulated Inflammatory and Degradative Proteins in Osteoarthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6441.	1.8	5
4	The Neuropeptide VIP Limits Human Osteoclastogenesis: Clinical Associations with Bone Metabolism Markers in Patients with Early Arthritis. <i>Biomedicines</i> , 2021, 9, 1880.	1.4	3
5	Profile of Matrix-Remodeling Proteinases in Osteoarthritis: Impact of Fibronectin. <i>Cells</i> , 2020, 9, 40.	1.8	43
6	A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 65.	1.8	35
7	Comparative Study of Senescent Th Biomarkers in Healthy Donors and Early Arthritis Patients. Analysis of VPAC Receptors and Their Influence. <i>Cells</i> , 2020, 9, 2592.	1.8	4
8	An Overview of VPAC Receptors in Rheumatoid Arthritis: Biological Role and Clinical Significance. <i>Frontiers in Endocrinology</i> , 2019, 10, 729.	1.5	17
9	Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patients. <i>Scientific Reports</i> , 2019, 9, 7383.	1.6	12
10	SAT0032â€¦ACTIVATION OF TH LYMPHOCYTES ALTERS THE PATTERN EXPRESSION AND CELLULAR LOCATION OF VIP RECEPTORS IN HEALTHY DONORS AND EARLY ARTHRITIS PATIENTS. , 2019, , .		0
11	The Anti-Inflammatory Mediator, Vasoactive Intestinal Peptide, Modulates the Differentiation and Function of Th Subsets in Rheumatoid Arthritis. <i>Journal of Immunology Research</i> , 2018, 2018, 1-11.	0.9	35
12	FRI0016â€¦Involvement of runx-2 and Î²-catenin signaling in the production of adamts-7 and adamts-12 in osteoarthritic synovial fibroblasts. , 2017, , .		0
13	Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12. <i>American Journal of Pathology</i> , 2016, 186, 2449-2461.	1.9	33
14	VIP and CRF reduce ADAMTS expression and function in osteoarthritis synovial fibroblasts. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 678-687.	1.6	12
15	VIP impairs acquisition of the macrophage proinflammatory polarization profile. <i>Journal of Leukocyte Biology</i> , 2016, 100, 1385-1393.	1.5	28
16	The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP. <i>Journal of Molecular Medicine</i> , 2015, 93, 457-467.	1.7	29
17	VIP Modulates IL-22R1 Expression and Prevents the Contribution of Rheumatoid Synovial Fibroblasts to IL-22-Mediated Joint Destruction. <i>Journal of Molecular Neuroscience</i> , 2014, 52, 10-17.	1.1	19
18	Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 512-525.	1.1	20

#	ARTICLE	IF	CITATIONS
19	IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts. <i>Rheumatology</i> , 2013, 52, 2177-2186.	0.9	59
20	Inflammatory Mediators Alter Interleukin-17 Receptor, Interleukin-12 and -23 Expression in Human Osteoarthritic and Rheumatoid Arthritis Synovial Fibroblasts: Immunomodulation by Vasoactive Intestinal Peptide. <i>NeuroImmunoModulation</i> , 2013, 20, 274-284.	0.9	24
21	Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. <i>Immunology and Cell Biology</i> , 2012, 90, 178-186.	1.0	27
22	CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts. <i>Cytokine</i> , 2011, 53, 184-190.	1.4	44
23	Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: Effect of vasoactive intestinal peptide. <i>Journal of Cellular Physiology</i> , 2011, 226, 3261-3269.	2.0	16
24	RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: Immune regulation by vasoactive intestinal peptide. <i>Arthritis and Rheumatism</i> , 2011, 63, 1626-1636.	6.7	59
25	Peptides Targeting Toll-Like Receptor Signalling Pathways for Novel Immune Therapeutics. <i>Current Pharmaceutical Design</i> , 2010, 16, 1063-1080.	0.9	39
26	New insights into the role of VIP on the ratio of T cell subsets during the development of autoimmune diabetes. <i>Immunology and Cell Biology</i> , 2010, 88, 734-745.	1.0	39
27	Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2008, 58, 1086-1095.	6.7	68
28	VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. <i>Molecular Immunology</i> , 2008, 45, 3065-3073.	1.0	45
29	Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis. <i>Brain, Behavior, and Immunity</i> , 2008, 22, 312-317.	2.0	28
30	Regulation of TLR expression, a new perspective for the role of VIP in immunity. <i>Peptides</i> , 2007, 28, 1825-1832.	1.2	34
31	CXCL12 is displayed by rheumatoid endothelial cells through its basic amino-terminal motif on heparan sulfate proteoglycans. <i>Arthritis Research and Therapy</i> , 2006, 8, R43.	1.6	50
32	VIP Decreases TLR4 Expression Induced by LPS and TNF- $\alpha$ Treatment in Human Synovial Fibroblasts. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 359-364.	1.8	24
33	VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. <i>Rheumatology</i> , 2006, 45, 527-532.	0.9	79
34	Topical Application of a Peptide Inhibitor of Transforming Growth Factor- $\beta$ 1 Ameliorates Bleomycin-Induced Skin Fibrosis. <i>Journal of Investigative Dermatology</i> , 2005, 125, 450-455.	0.3	149
35	Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K. <i>Prostate</i> , 2005, 63, 44-55.	1.2	45
36	Coexpression of AT1 and AT2 receptors by human fibroblasts is associated with resistance to angiotensin II. <i>Peptides</i> , 2005, 26, 1647-1653.	1.2	7

#	ARTICLE	IF	CITATIONS
37	Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2005, 7, R1034.	1.6	104
38	Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. <i>British Journal of Rheumatology</i> , 2004, 43, 416-422.	2.5	62
39	Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. <i>Regulatory Peptides</i> , 2004, 119, 69-75.	1.9	41
40	VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. <i>British Journal of Pharmacology</i> , 2003, 139, 1050-1058.	2.7	57
41	Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. <i>Cellular Signalling</i> , 2001, 13, 887-894.	1.7	36